neurology

News

FDA approves Lilly's new migraine attack drug, rival from Al...

The FDA has approved Eli Lilly’s new migraine drug lasmiditan, offering patients a new option to relieve symptoms should they feel an attack coming on.

News

After Alzheimer's trial woes, Biogen's R&D chief quits to he...

Michael Ehlers is to quit as head of Biogen’s troubled R&D outfit, taking a role as chief executive of New York-based venture capitalist Apple Tree Partners.

News

GW Pharma's cannabis-derived epilepsy drug approved in EU

GW Pharmaceuticals’ cannabis-derived drug Epidyolex has been approved in Europe for two kinds of rare childhood epilepsy.

News

bluebird presents long-term data from CALD gene therapy

bluebird bio has produced updated data from its gene therapy for the rare genetic neurological disease cerebral adrenoleukodystrophy (CALD), showing that it continues to work in the long-te

News

Lundbeck to acquire Alder, and migraine drug, for $1.95bn

Lundbeck is to acquire Alder BioPharmaceuticals and its late-stage migraine drug eptinezumab in a deal worth up to $1.95 billion.

R&D

Citing phase 2 figures, Axon looks for big pharma investment...

After trial failure upon trial failure in Alzheimer's disease will big pharma be prepared to fund a trial using a new approach instead of the amyloid-targeting drugs, that have caused so mu

FDA approves Lilly's new migraine attack drug, rival from Al...

After Alzheimer's trial woes, Biogen's R&D chief quits to he...

GW Pharma's cannabis-derived epilepsy drug approved in EU

bluebird presents long-term data from CALD gene therapy

Lundbeck to acquire Alder, and migraine drug, for $1.95bn

Citing phase 2 figures, Axon looks for big pharma investment...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

neurology

Editor's Picks